{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:58:52Z","timestamp":1787500732448,"version":"build-2736575974"},"reference-count":63,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2022,10,2]]},"DOI":"10.1080\/14728214.2022.2149735","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T04:18:37Z","timestamp":1669004317000},"page":"379-387","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Emerging drugs for the treatment of alopecia areata"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-8880","authenticated-orcid":false,"given":"Hassiel Aurelio","family":"Ram\u00edrez-Mar\u00edn","sequence":"first","affiliation":[{"name":"Department of Dermatology, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5516-4043","authenticated-orcid":false,"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[{"name":"Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-020-00673-w"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14073"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01845-0"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.004"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2018.1444750"},{"issue":"6","key":"cit0006","first-page":"609","volume":"154","author":"Rossi A","year":"2019","journal-title":"G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2017.107"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100051"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.04.003"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004413.pub2"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2015.46"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500973"},{"issue":"1","key":"cit0014","first-page":"21","volume":"194","author":"Villarino AV","year":"2015","journal-title":"J Immunol Baltim Md 1950"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.03.008"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.1142"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.260"},{"key":"cit0018","unstructured":"FDA. FDA approves first systemic treatment for alopecia areata. 2022. [cited 2022 Jun 22]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-systemic-treatment-alopecia-areata."},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652191"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1522"},{"key":"cit0021","unstructured":"clinicaltrials.gov. Phase 2 trial of BNZ-1 in patients with moderate to severe alopecia areata. 2021. [cited 2022 Jun 08]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03532958"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01694"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3685"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S309215"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776"},{"key":"cit0027","unstructured":"clinicaltrials.gov. Study to evaluate the efficacy of tofacitinib in moderate to severe alopecia areata. Totalis And Universalis. 2019. [cited 2022 Jun 08]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02299297."},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14422"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1702878"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.032"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15937"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.006"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisp.2017.10.003"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14855"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.050"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2203440"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.045"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.040"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S334727"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1002\/art.41316"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17984"},{"key":"cit0042","unstructured":"clinicaltrials.gov. PF-06651600 for the Treatment of alopecia areata (ALLEGRO-2b\/3). 2022. [cited 2022 Jun 08]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03732807."},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.2012149"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15605"},{"key":"cit0045","unstructured":"clinicaltrials.gov. ATI-501 oral suspension compared to placebo in subjects with alopecia areata, alopecia universalis or alopecia totalis. 2020. [cited 2022 Jun 08]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03594227"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.604314"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15346"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000780"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13836"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.016"},{"key":"cit0051","unstructured":"clinicaltrials.gov. A study with jaktinib hydrochloride cream applied topically to subjects with alopecia areata (AA) .2022. [cited 2022 Jun 08]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04445363."},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02336-0"},{"key":"cit0053","unstructured":"clinicaltrials.gov. Efficacy of twice daily application of LEO 124249 ointment 30 mg\/g for 12 weeks on eyebrow alopecia areata. 2018. [cited 2022 Jun 08] Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03325296."},{"key":"cit0054","unstructured":"clinicaltrials.gov. A study of ATI-50002 topical solution for the treatment of alopecia areata. 2020. [cited 2022 Jun 08]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03354637"},{"key":"cit0055","unstructured":"HorizonTherapeutics. Daxdilimab (HZN-7734) Mechanism of action. Horizontherapeutics.com. 2021. [cited 2022 Jun 08]. Available from: https:\/\/www.horizontherapeutics.com\/Media-Center\/Video-Library\/Daxdilimab-Mechanism-of-Action"},{"key":"cit0056","unstructured":"clinicaltrials.gov. Study of DAXDILIMAB for the treatment of moderate-to-severe alopecia areata. 2022. [cited 2022 Jun 07]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05368103."},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712"},{"key":"cit0059","unstructured":"AnaptysBio. ROSNILIMAB. 2022 [cited 2022 Jun 07]. Available from: https:\/\/www.anaptysbio.com\/pipeline\/rosnilimab\/"},{"key":"cit0060","unstructured":"clinicaltrials.gov. A study to evaluate the efficacy and safety of rosnilimab (ANB030) in treatment of subjects with moderate-to-severe alopecia areata (AZURE). 2022.[cited 2022 Jun 07]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05205070."},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01528-8"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.11.008"},{"key":"cit0063","unstructured":"clinicaltrials.gov. Safety and efficacy of oral etrasimod in adult participants with moderate-to-severe alopecia areata. 2022. [cited 2022 Jul 06] Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04556734."}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2022.2149735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T03:47:35Z","timestamp":1677642455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2022.2149735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,2]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10,2]]}},"alternative-id":["10.1080\/14728214.2022.2149735"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2022.2149735","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}